Patents Assigned to Pierre Fabre Medicament
  • DERIVATIVES OF MACROCYCLIC N-ARYL-2-AMINO-4-ARYL-PYRIMIDINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK
    Publication number: 20170281622
    Abstract: The present invention relates to a compound with the following formula: formula (I) or a salt and/or a pharmaceutically acceptable solvate thereof, in particular for use as a drug, in particular in the treatment of cancer, as well as to the pharmaceutical compositions that contain same and to the methods for preparing same.
    Type: Application
    Filed: September 2, 2015
    Publication date: October 5, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: El Bachir KALOUN, Serge GRISONI, Bruno GOMES, Philippe SCHMITT
  • IGF-1R ANTIBODY AND ITS USE AS ADDRESSING VEHICLE FOR THE TREATMENT OF CANCER
    Publication number: 20170267766
    Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
    Type: Application
    Filed: April 27, 2015
    Publication date: September 21, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Liliane GOETSCH, Matthleu BROUSSAS, Charlotte BEAU-LARVOR, Thierry CHAMPION, Alain ROBERT
  • ISOQUINOLINONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER
    Publication number: 20170240544
    Abstract: The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as a drug, notably in the treatment of cancer, as well as pharmaceutical compositions containing such a compound and processes to prepare such a compound.
    Type: Application
    Filed: September 2, 2015
    Publication date: August 24, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: El Bachir KALOUN, Philippe SCHMITT, Anna KRUCZYNSKI
  • METHOD FOR TREATING MOVEMENT DISORDERS WITH BEFIRADOL
    Publication number: 20170239231
    Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, where in the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
    Type: Application
    Filed: July 9, 2015
    Publication date: August 24, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Bruno PAILLARD, Laurence DEL FRARI, Valérie BRUNNER, Adrian NEWMAN TANCREDI, Mark VARNEY
  • ANTI-cMET ANTIBODY
    Publication number: 20170218071
    Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
    Type: Application
    Filed: September 7, 2016
    Publication date: August 3, 2017
    Applicant: Pierre Fabre Medicament
    Inventors: Liliane Goetsch, Thierry Wurch, Cédric Bes
  • Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs
    Patent number: 9687459
    Abstract: The present inventions concerns derivatives of aminocyclobutane, particularly as NMDA receptor antagonists, their application in human therapy and their method of preparation. These compounds correspond to the general formula (1): wherein: X1 represents a hydrogen atom or fluorine atom; X2 is a hydrogen atom or fluorine atom or chlorine atom; R1 represents a hydrogen atom or fluorine atom or chlorine atom or methyl group or methoxy group or cyano group; R2 represents independently or together a methyl group or ethyl group.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: June 27, 2017
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Bernard Vacher, Elodie Blanc, Ronan Depoortere
  • Process for the modulation of the antagonistic activity of a monoclonal antibody
    Patent number: 9676839
    Abstract: The present disclosure relates to the antibody engineering field and, more particularly, to a process for the screening of antibodies and/or the modulation of the agonistic/antagonistic activity of antibodies. More particularly, the disclosure concerns a process of improving the antagonistic activity of a monoclonal antibody directed against a specific target molecule, or a divalent functional fragment or derivative thereof, the antibody being capable of inhibiting one or more of the biological activities of the target molecule, wherein the process comprises a stage of reconfiguration of the hinge region consisting of a modification of the amino acid sequence of the hinge region by the deletion, the addition or the substitution of at least one amino acid. The disclosure also relates to polypeptides useful for such a modulation method and the obtained antibodies.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: June 13, 2017
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Liliane Goetsch, Thierry Wurch
  • Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer
    Patent number: 9669106
    Abstract: The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: June 6, 2017
    Assignee: Pierre Fabre Medicament
    Inventors: Liliane Goetsch, Alexandra Jouhanneaud, Michel Perez
  • FLAVAGLINE DERIVATIVES
    Publication number: 20170137400
    Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
    Type: Application
    Filed: July 6, 2015
    Publication date: May 18, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Frédéric MARION, El Bachir KALOUN, Frédéric LIEBY-MULLER, Michel PEREZ, Jean-Philippe ANNEREAU, Laurent CREANCIER
  • CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER
    Publication number: 20170112943
    Abstract: The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.
    Type: Application
    Filed: October 26, 2015
    Publication date: April 27, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Liliane Goetsch, Alexandra Jouhanneaud, Michel Perez
  • Antigen binding proteins
    Patent number: 9624308
    Abstract: The present invention relates to novel antigen binding proteins, in particular monoclonal antibodies, capable of binding to the protein Axl as well as the amino and nucleic acid sequences coding for said proteins. From one aspect, the invention relates to novel antigen binding proteins, or antigen binding fragments, capable of binding to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding proteins as addressing products in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: April 18, 2017
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Charlotte Beau-Larvor, Liliane Goetsch, Nicolas Boute
  • Use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine for treating cancer and in particular for preventing and/or treating cancer metastases
    Patent number: 9603835
    Abstract: The present invention relates to the use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methyl-propyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine or one of the pharmaceutically acceptable salts thereof for treating cancer and particularly in preventing and/or treating cancerous metastases.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: March 28, 2017
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Bernard Vacher, Bruno Le Grand
  • AMINOCYCLOBUTANE DERIVATIVES, METHOD FOR PREPARING SAME AND THE USE THEREOF AS DRUGS
    Publication number: 20170065543
    Abstract: The present inventions concerns derivatives of aminocyclobutane, particularly as NMDA receptor antagonists, their application in human therapy and their method of preparation. These compounds correspond to the general formula (1): wherein: X1 represents a hydrogen atom or fluorine atom; X2 is a hydrogen atom or fluorine atom or chlorine atom; R1 represents a hydrogen atom or fluorine atom or chlorine atom or methyl group or methoxy group or cyano group; R2 represents independently or together a methyl group or ethyl group.
    Type: Application
    Filed: September 12, 2016
    Publication date: March 9, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Bernard VACHER, Elodie BLANC, Ronan DEPOORTERE
  • ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER
    Publication number: 20170043032
    Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: April 27, 2015
    Publication date: February 16, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW
  • IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER
    Publication number: 20170043031
    Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: April 27, 2015
    Publication date: February 16, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Mathieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW, Thierry CHAMPION, Alain ROBERT
  • NOVEL ANTI ADAM17 ANTIBODY AND ITS USE FOR THE TREATMENT OF CANCER
    Publication number: 20160326257
    Abstract: The present invention relates to a novel antibody capable of binding to ADAM17 and also the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to a novel antibody, or antigen-binding fragments, capable of binding to ADAM17 with anti-tumour activities. The invention also comprises the use of said antibody as a drug for the treatment of cancer. Finally, the invention comprises compositions comprising said antibody, alone or in combination or conjugation with other anti-cancer compounds, and the use of same for the treatment of cancer.
    Type: Application
    Filed: December 24, 2014
    Publication date: November 10, 2016
    Applicant: PIERRE FABRE MEDICAMENT
    Inventor: Peter LOWE
  • Bacterium and extracts of said bacterium and the use of same in therapy
    Patent number: 9486486
    Abstract: The present invention relates to a novel bacterial strain isolated and characterized from groundwater. The invention also relates to bacterial extracts and to the therapeutic use of same, notably in the context of the treatment of inflammations.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: November 8, 2016
    Assignees: PIERRE FABRE DERMO-COSMETIQUE, PIERRE FABRE MEDICAMENT
    Inventors: Nathalie Castex-Rizzi, Thien Nguyen, Christine Libon, Bertrand Chol
  • CHROMONE DERIVATIVE AS A DOPAMINE D3 RECEPTOR ANTAGONIST FOR ITS USE FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER
    Publication number: 20160303117
    Abstract: The present invention claims a chromone derivative and pharmaceutical compositions and combinations comprising a least the said derivative, which is a dopamine D3 receptor antagonist, for their use for the treatment of autism spectrum disorder.
    Type: Application
    Filed: December 12, 2014
    Publication date: October 20, 2016
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Agnès AUCLAIR, Paul MOSER, Pierre SOKOLOFF
  • Anti-cMET antibody
    Patent number: 9469691
    Abstract: Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: October 18, 2016
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Liliane Goetsch, Thierry Wurch, Cédric Bes
  • Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs
    Patent number: 9469601
    Abstract: The present inventions concerns derivatives of aminocyclobutane, particularly as NMDA receptor antagonists, their application in human therapy and their method of preparation. These compounds correspond to the general formula (1): wherein: X1 represents a hydrogen atom or fluorine atom; X2 is a hydrogen atom or fluorine atom or chlorine atom; R1 represents a hydrogen atom or fluorine atom or chlorine atom or methyl group or methoxy group or cyano group; R2 represents independently or together a methyl group or ethyl group.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: October 18, 2016
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Bernard Vacher, Elodie Blanc, Ronan Depoortere